Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

作者：Krisztina M. Papp‐Wallace, Nhu Q. Nguyen, Michael R. Jacobs, Christopher R. Bethel, Melissa D. Barnes, Vijay Kumar, Saralee Bajaksouzian, Susan D. Rudin, Philip N. Rather, Satish Bhavsar, Ravikumar Tadiparthi, Prasad Deshpande, Vijay Patil, Ravindra Yeole, Sachin Bhagwat, Mahesh Patel, Focco van den Akker, Robert A. Bonomo · 发表于：Journal of Medicinal Chemistry · 年份：2018 · DOI：10.1021/acs.jmedchem.8b00091 · 被引用次数：151 · 研究领域：Antibiotic Resistance in Bacteria、Pneumocystis jirovecii pneumonia detection and treatment、Nephrotoxicity and Medicinal Plants

Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107), and WCK 4234 (compounds 1 – 3, respectively), were synthesized and biochemically characterized against clinically important bacteria. Compound 3 inhibited class A, C, and D β-lactamases with unprecedented k 2 / K values against OXA carbapenemases. Compounds 1 and 2 acylated class A and C β-lactamses rapidly but not the tested OXAs. Compounds 1 – 3 formed highly stable acyl-complexes as demonstrated by mass spectrometry. Crystallography revealed that 1 – 3 complexed with KPC-2 adopted a “chair conformation” with the sulfate occupying the carboxylate binding region. The cefepime- 2 and meropenem- 3 combinations were effective in murine peritonitis and neutropenic lung infection models caused by MDR Acinetobacter baumannii . Compounds 1 – 3 are novel β-lactamase inhibitors that demonstate potent cross-class inhibition, and clinical studies targeting MDR infections are warranted.